Kenvue Inc.

KVUE

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Deerfield Management Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$238K

1 fund

Feb 17, 2026

$1.1M

1 fund

+374% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 65,344Value: $1.1M

**Signal Note: Deerfield Management Initiates KVUE Position** Deerfield's $1.1M entry into Kenvue (consumer health spin-co from J&J) suggests conviction in the standalone OTC portfolio or potential M&A upside, though the position size is modest relative to Deerfield's typical healthcare allocations. No imminent clinical catalyst is apparent; value likely hinges on margin expansion, portfolio optimization, or strategic consolidation in the fragmented OTC/consumer health market.

Eventide Asset ManagementNEWFeb 13, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

EHC2 funds DOCS2 funds EW2 funds CELC2 funds IRON2 funds BBIO2 funds ARWR2 funds STE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Eventide Initiates KVUE Position Eventide's entry into Kenvue—a $4.3B consumer health spinoff from J&J (2023)—signals conviction in OTC portfolio stabilization and potential M&A optionality in the fragmented consumer wellness space. The position timing coincides with KVUE's operational normalization post-spin and potential activist interest, though the company lacks pipeline catalysts typical of Eventide's biotech focus, suggesting this reflects portfolio diversification rather than clinical innovation.